Bayer’s compulsory licence appeal date set
Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Bayer’s compulsory licence appeal date set

India’s Intellectual Property Appellate Board will hear Bayer’s appeal of a controversial compulsory licence ruling on August 21 in Chennai, according to Pharmabiz.com

The Controller of Patents issued a compulsory licence in March to domestic generic drug maker Natco for the cancer treatment drug sorafenib.

The German pharmaceutical company filed its appeal with the country’s Intellectual Property Appellate Board on May 4.

The compulsory licence is in force for the remaining term of the patent licence and requires Natco to pay a royalty rate of 6% of net sales of the drug.

The Controller said in March that he was granting the compulsory licence on the grounds (a) that the reasonable requirements of the public with respect to the patented invention had not been satisfied, (b) that the patented invention was not available to the public at a reasonably affordable price, and (c) that the patented invention was not being worked in India.

Bayer attacked the Patent Controller’s ruling in a statement, saying that it “damages the international patent system and endangers pharmaceutical research”.

For more of Managing IP’s coverage of the case, click here and here. More details are available on Pharmabiz.com.

more from across site and ros bottom lb

More from across our site

A 36-member team from Zhong Lun Law Firm, including six partners, will join the newly formed East IP Group
The Delhi High Court sided with Ericsson against Indian smartphone maker Lava, bringing the companies' nine-year dispute to a close
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
Tennessee has passed the ELVIS Act, a law that fights against AI models that mimic the voice and likeness of music artists
Rob Stien, chief communications and public policy officer at InterDigital, says the EU has forgotten innovators while trying to solve an issue that doesn’t exist
As Australia’s Qantm IP leans towards being acquired by a private equity company, sources discuss what it could mean for IP firms
Law firms that are conscious of their role in society are more likely to win work, according to a survey of over 23,000 in-house professionals
Nghiem Xuan Bac Pham, managing partner of Vision & Associates, discusses opportunities created by the US-China rift as well as profitability issues facing IP practices
Douglas Leite and two of his colleagues were intrigued by Bhering Advogados’s mission to grow its patent litigation practice
Each week Managing IP speaks to a different IP practitioner about their life and career
Gift this article